7,926 reports of this reaction
2.7% of all NATALIZUMAB reports
#8 most reported adverse reaction
MEMORY IMPAIRMENT is the #8 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 7,926 FDA adverse event reports linking NATALIZUMAB to MEMORY IMPAIRMENT. This represents approximately 2.7% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience memory impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MEMORY IMPAIRMENT is a less commonly reported adverse event for NATALIZUMAB, but still significant enough to appear in the safety profile.
In addition to memory impairment, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to memory impairment in FDA adverse event reports:
MEMORY IMPAIRMENT has been reported as an adverse event in 7,926 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MEMORY IMPAIRMENT accounts for approximately 2.7% of all adverse event reports for NATALIZUMAB, making it a notable side effect.
If you experience memory impairment while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.